University of Bonn-ko ikertzaileekin lankidetzan egindako argitalpenak (29)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

2015

  1. Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study

    PLoS ONE, Vol. 10, Núm. 10

  2. Faldaprevir and pegylated interferon α-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV

    AIDS, Vol. 29, Núm. 5, pp. 571-581

  3. Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: A randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents

    HIV Clinical Trials, Vol. 16, Núm. 2, pp. 72-80

2014

  1. High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance

    HIV Medicine, Vol. 15, Núm. 10, pp. 615-620

2013

  1. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?

    Journal of Hepatology, Vol. 59, Núm. 2, pp. 213-220

  2. Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients

    Clinical Infectious Diseases, Vol. 56, Núm. 8, pp. 1117-1122

  3. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

    PLoS ONE, Vol. 8, Núm. 5

  4. Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapy

    HIV Medicine, Vol. 14, Núm. 6, pp. 370-378

  5. Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA

    HIV Medicine, Vol. 14, Núm. 10, pp. 614-623

2012

  1. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

    AIDS, Vol. 26, Núm. 15, pp. 1917-1926

  2. Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load

    Journal of Hepatology, Vol. 56, Núm. 4, pp. 788-794

  3. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA study

    PLoS ONE, Vol. 7, Núm. 7

2011

  1. An international collaboration to standardize HIV-2 viral load assays: Results from the 2009 ACHI EV 2E quality control study

    Journal of Clinical Microbiology, Vol. 49, Núm. 10, pp. 3491-3497

  2. Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients

    AIDS, Vol. 25, Núm. 18, pp. 2197-2208

  3. Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype

    HIV Medicine, Vol. 12, Núm. 8, pp. 487-493

  4. Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study)

    HIV Medicine, Vol. 12, Núm. 6, pp. 374-382

2010

  1. Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 3, pp. 548-555

2009

  1. Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppression

    Journal of Acquired Immune Deficiency Syndromes, Vol. 50, Núm. 5, pp. 457-463

  2. When and how to use maraviroc in HIV-infected patients

    AIDS, Vol. 23, Núm. 18, pp. 2377-2385